Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;51:560-566
Published online before print January 7, 2008, doi: 10.1161/HYPERTENSIONAHA.107.102590
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/2/560    most recent
HYPERTENSIONAHA.107.102590v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qian, J.-Y.
Right arrow Articles by LaPointe, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qian, J.-Y.
Right arrow Articles by LaPointe, M. C.
Related Collections
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression

(Hypertension. 2008;51:560.)
© 2008 American Heart Association, Inc.


Original Articles Part 2

Reduced Cardiac Remodeling and Function in Cardiac-Specific EP4 Receptor Knockout Mice With Myocardial Infarction

Jian-Yong Qian; Pamela Harding; Yunhe Liu; Ed Shesely; Xiao-Ping Yang; Margot C. LaPointe

From the Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, Mich.

Correspondence to Margot C. LaPointe, Hypertension and Vascular Research Division, E&R Building #7121, Department of Internal Medicine, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202-2689. E-mail mlapoin1{at}hfhs.org

We have shown previously that cyclooxygenase-2 inhibition reduces cardiac hypertrophy and fibrosis postmyocardial infarction (MI) in a mouse model and that prostaglandin E2 stimulates cardiomyocyte hypertrophy in vitro through its EP4 receptor. Because the role of cardiac myocyte EP4 in cardiac function and hypertrophy in vivo is unknown, we generated mice lacking EP4 only in cardiomyocytes (CM- EP4 knockout [KO]). Twelve- to 14-week–old mice were evaluated using echocardiography and histology. There were no differences in ejection fraction, myocyte cross-sectional area, and interstitial collagen fraction between KO mice and littermate controls. To test the hypothesis that EP4 is involved in cardiac remodeling after MI, we induced MI by ligating the left anterior descending coronary artery. Two weeks later, the mice were subjected to echocardiography, and hearts were removed for histology and Western blot. There was no difference in infarct size between KO mice and controls; however, KO mice showed less myocyte cross-sectional area and interstitial collagen fraction than controls. Also, CM-EP4 KO mice had reduced ejection fraction. Because the transcription factor Stat-3 is involved in hypertrophy and protection from ischemic injury, we tested whether it was activated in control and KO mouse hearts after MI. Western blot indicated that Stat-3 was activated in control hearts after MI but not in KO hearts. Thus, CM-EP4 deletion decreased hypertrophy, fibrosis, and activation of Stat-3. However, cardiac function was unexpectedly worsened in these mice. We conclude that cardiac myocyte EP4 plays a role in hypertrophy via activation of Stat-3, a process that seems to be cardioprotective.


Key Words: PG receptor • hypertrophy • EP4 • PGE • MI, remodeling




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Wang, V. V. Patel, E. Ricciotti, R. Zhou, M. D. Levin, E. Gao, Z. Yu, V. A. Ferrari, M. M. Lu, J. Xu, et al.
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function
PNAS, May 5, 2009; 106(18): 7548 - 7552.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
E. M. Smyth, T. Grosser, M. Wang, Y. Yu, and G. A. FitzGerald
Prostanoids in health and disease
J. Lipid Res., April 1, 2009; 50(Supplement): S423 - S428.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Meyer-Kirchrath, M. Martin, C. Schooss, C. Jacoby, U. Flogel, A. Marzoll, J. W. Fischer, J. Schrader, K. Schror, and T. Hohlfeld
Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart
Cardiovasc Res, February 1, 2009; 81(2): 310 - 318.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour, and U. Lang
The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis
Cardiovasc Res, October 1, 2008; 80(1): 69 - 77.
[Abstract] [Full Text] [PDF]